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suggests that the regulation of mGluR5, including its interaction with trafficking molecules, may be altered 
in the disorder. However there have been no investigations of hippocampal mGluR5 or mGluR5 trafficking 
molecules in the postmortem schizophrenia brain to confirm this. In the present study, we investigated 
whether protein expression of mGluR5, as well as Norbin and Tamalin (modulators of mGluR5 signalling 
and trafficking), might be altered in the schizophrenia brain, using postmortem samples from the 
hippocampal CA1 region of schizophrenia subjects and matched controls (n = 20/group). Protein levels of 
mGluR5 (total: 42%, p < 0.001; monomer: 25%, p = 0.011; dimer: 52%, p < 0.001) and mGluR5 trafficking 
molecules (Norbin: 47%, p < 0.001; Tamalin: 34%, p = 0.009) were significantly higher in schizophrenia 
subjects compared to controls. To determine any influence of antipsychotic drug treatment, all proteins 
were also correlated with lifetime chlorpromazine equivalents in patients, and separately measured in the 
hippocampus of rats exposed to haloperidol or olanzapine treatment. mGluR5 was negatively correlated 
with lifetime antipsychotic drug exposure in schizophrenia patients, suggesting antipsychotic drugs could 
reduce mGluR5 protein in schizophrenia subjects. In contrast, mGluR5 and mGluR5 trafficking molecules 
were not altered in the hippocampus of antipsychotic drug treated rats. This investigation provides strong 
support for the hypothesis that mGluR5 is involved in the pathology of schizophrenia, and that alterations 
to mGluR5 trafficking might contribute to the hippocampal-dependent cognitive dysfunctions associated 
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Abstract 
Metabotropic glutamate receptor 5 (mGluR5) is involved in hippocampal-dependent learning and 
memory, which are processes disrupted in schizophrenia. Recent evidence from human genetic and 
animal studies suggests that the regulation of mGluR5, including its interaction with trafficking 
molecules, may be altered in the disorder. However there have been no investigations of hippocampal 
mGluR5 or mGluR5 trafficking molecules in the postmortem schizophrenia brain to confirm this. In 
the present study, we investigated whether protein expression of mGluR5, as well as Norbin and 
Tamalin (modulators ofmGluR5 signalling and trafficking), might be altered in the schizophrenia 
brain, using postmortem samples from the hippocampal CA1 region of schizophrenia subjects and 
matched controls (n = 20/group). Protein levels of mGluR5 (total: 42%, p < 0.001; monomer: 25%, p 
= 0.011; dimer: 52%, p < 0.001) and mGluR5 trafficking molecules (Norbin: 47%, p < 0.001; 
Tamalin: 34%, p = 0.009) were significantly higher in schizophrenia subjects compared to controls. 
To determine any influence of antipsychotic drug treatment, all proteins were also correlated with 
lifetime chlorpromazine equivalents in patients, and separately measured in the hippocampus of rats 
exposed to haloperidol or olanzapine treatment. mGluR5 was negatively correlated with lifetime 
antipsychotic drug exposure in schizophrenia patients, suggesting antipsychotic drugs could reduce 
mGluR5 protein in schizophrenia subjects. In contrast, mGluR5 andmGluR5 trafficking molecules 
were not altered in the hippocampus of antipsychotic drug treated rats. This investigation provides 
strong support for the hypothesis that mGluR5 is involved in the pathology of schizophrenia, and that 
alterations to mGluR5 trafficking might contribute to the hippocampal-dependent cognitive 
dysfunctions associated with this disorder. 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
Metabotropic glutamate receptor subtype 5 (mGluR5) is a postsynaptic G-protein coupled 
receptor (GPCR), best known for its ability to modulate postsynaptic currents induced by 
the ionotropic N-methyl-D-aspartate glutamate receptor (NMDAR; Matosin and Newell, 2013). A 
substantial body of evidence indicates that mGluR5 is critically involved in hippocampal-dependent 
learning and memory. Specifically, several studies have reported that hippocampal mGluR5 activity is 
important for long-term potentiation(LTP) and long-term depression (LTD), molecular mechanisms 
underpinning synaptic plasticity (see Mukherjee and Manahan-Vaughan, 2013). mGluR5 knockout 
mice display reduced LTP, specifically in the hippocampal cornu ammonis 1 (CA1) region, as well as 
deficits in spatial learning and memory (Lu et al., 1997). Chronic mGluR5 antagonism in rats 
similarly induces deficits in LTP in the CA1 region, which correlates with reduced hippocampal 
mGluR5 protein levels and poorer working and reference memory (Manahan-Vaughan and 
Braunewell, 2005). Accordingly, mGluR5 positive allosteric modulators (PAMs) enhance the balance 
of hippocampal LTP and LTD at CA1 synapses, and consequently improve spatial learning in mice 
(Ayala et al., 2009). Notably, very recent evidence suggests localisation of mGluR5 in this region 
might modulate the direction or balance of synaptic plasticity (e.g. LTP versus LTD; Purgert et al., 
2014). 
 
Despite extensive examination in animal models, the status of hippocampal mGluR5 protein in 
patients with schizophrenia is largely unknown. Only one study has previously investigated mGluR5 
mRNA expression in the hippocampus of schizophrenia subjects (in a small postmortem cohort of 5 
schizophrenia subjects and 6 controls), reporting decreased mGluR5 expression in 
the parahippocampal gyrus, and no alterations in the dentate gyrus, CA1, CA3 or CA4 (Ohnuma et 
al., 2000). Based on studies indicating the importance of mGluR5 in synaptic plasticity, including 
reports that suggest mGluR5 deficits lead to schizophrenia-like cognitive dysfunctions, it is important 
to extend on these works and thoroughly investigate whether hippocampal mGluR5 is altered in 
schizophrenia, specifically at the protein level, as this might contribute to the manifestation of 
learning and memory deficits observed in patients with schizophrenia. 
 
Accumulating evidence indicates the importance of mGluR5 protein–protein interactions in the 
regulation of mGluR5 trafficking, internalisation and signalling (Enz, 2007). The first discovered 
modulator of mGluR5 was Homer1 (Brakeman et al., 1997), which has since been extensively studied 
in the context of schizophrenia (Szumlinski et al., 2006). Both Homer1 protein and gene are reported 
as altered in, or associated with, schizophrenia (Engmann et al., 2011 and Spellmann et al., 2011). 
However, in recent years, other molecules that modulate mGluR5 localisation and traficking have 
become apparent. The neuron-specific protein Norbin (neurochondrin) plays a critical role in mGluR5 
localisation, and positively regulates mGluR5 signalling. Interestingly, Norbin knockout was found to 
reduce mGluR5-dependent LTP and abolished LTD in CA1 synapses (Wang et al., 2009). In cultured 
mouse hippocampal CA1/CA3 neurons, the multiscaffold protein Tamalin also proved critical to 
 
mGluR5 neuritic localisation processes ( Kitano et al., 2002) and deletion of the Tamalin binding site 
on mGluR5 induced mGluR5 internalisation in cellular assays (Timms et al., 2013). Furthermore, 
evidence from a schizophrenia pedigree suggests that mGluR5/Tamalin interactions might be 
disrupted in the disorder (Timms et al., 2013). As mGluR5 localisation appears to impact on mGluR5 
functions (Purgert et al., 2014), it is important to consider the possibility of altered mGluR5 
trafficking in the context of schizophrenia. However, the status of these mGluR5 trafficking 
molecules in any neuropsychiatric pathology, including schizophrenia, has not been assessed. 
 
In the present study, we therefore determined whether mGluR5 protein levels are altered in 
postmortem samples from the CA1 hippocampal region of schizophrenia subjects compared to 
healthy controls (n = 20/group). We further examined protein levels of the mGluR5 trafficking 
molecules Norbin and Tamalin, which collectively play an important role in mGluR5 trafficking, 
internalisation and signalling (Kitano et al., 2003 and Wang et al., 2009). The CA1 region was chosen 
for examination due to evidence that mGluR5-mediated LTP might be specific to CA1 synapses (Lu 
et al., 1997). Subsequently, we ascertained whether any observed changes in protein levels of 
mGluR5 or its trafficking molecules were influenced by antipsychotic drug (APD) treatment. For this 
purpose, we treated rats with first- and second-generation APDs (haloperidol and olanzapine 
respectively) and measured hippocampal protein levels of mGluR5, Norbin and Tamalin. 
2. Materials and methods 
2.1. Human postmortem brain samples and tissue preparation 
Postmortem human CA1 samples from 20 control (no history of psychiatric diagnosis) and 
20 schizophrenia subjects, diagnosed according to the Diagnostic and Statistical Manual of Mental 
Disorders IV (DSM-IV), were obtained from the New South Wales Brain Bank Network (Sydney, 
Australia). Subjects were matched according to tissue pH, postmortem interval, RNA integrity 
number (RIN) and age at death (Table 1). APD treatment premortem was standardised to a 
lifetime chlorpromazine equivalent for each patient, and antidepressant drug treatment history was 
specified on a qualitative scale (i.e. yes/no). The samples analysed in this study were derived from a 
cohort we previously used to examine mGluR5 (Brodmann's Area 46, n = 37/group; Matosin et al., 
2013). This work was approved by the Human Research Ethics Committees at the University of 
Wollongong (HE99/222) and the University of New South Wales (HREC 07261). Anatomical 
identification and preparation of this CA1 tissue have been previously described in detail (Fernandez-
Enright et al., 2014). 
 
 
 
 
 
 
Table 1. Demographic and clinical characteristics of the postmortem cohort. 
CA1 (n = 20/group) 
 
Control Schizophrenia 
Brain pH 6.6 ± 0.03 6.6 ± 0.3 
Postmortem interval (hours) 26.1 ± 12.8 28.8 ± 14.1 
RNA integrity number 7.2 ± 0.7 7.2 ± 0.5 
Age at death (years) 58.2 ± 12.6 55.5 ± 13.5 
Gender 2 F, 18 M 9 F, 11 M 
Hemisphere 13 R, 7 L 10 R, 10 L 
Age of disease onset (years) – 23.5 ± 6.8 
Duration of illness (years) – 32.05 ± 13.7 
Lifetime antipsychotic drug medicationa – 668 ± 421 
Antidepressant history (yes/no) – 12 
Abbreviations: DLPFC: dorsolateral prefrontal cortex; F: female; L: left; M: male; R: right. 
Data are expressed as mean ± standard deviation 
aStandardised chlorpromazine equivalent, mg. 
2.2. Animal housing, treatment and tissue preparation 
To assess the influence of haloperidol and olanzapine on mGluR5 and mGluR5 endogenous regulator 
expression, rats were treated with APD medication as previously described (Matosin et al., 2013). 
Briefly, adult (10 weeks of age) male Sprague-Dawley rats were purchased from the Animal Resource 
Centre (Perth, Australia). Rats were separated into groups according to the 3 treatments and 3 
treatment-durations (9 groups; n = 6/group). Animals were fed prepared food pellets (sweet cookie 
dough containing 62% carbohydrate, 22% protein, 10% vitamins, 6% fibre and minerals) 3 times/day 
at 8 hour intervals, containing either typical antipsychotic, haloperidol (0.1 mg/kg body weight; daily 
total 0.3 mg/kg), or atypical antipsychotic, olanzapine (1 mg/kg body weight; daily total 3 mg/kg), or 
vehicle control (no drug), for short term (8 days), medium term (15 days) and long term (35 days) 
durations. Food and water were available ad libitum, and consumption of food pellets was visually 
validated. APD doses were chosen to model a clinical setting (Han et al., 2008 and Weston-Green et 
al., 2012). 
 
Forty-eight hours after final treatment, rats were euthanised using carbon dioxide asphyxiation. 
The hippocampus (Bregma − 2.30 to − 5.20; total of dorsal and ventral regions) was dissected on ice, 
snap frozen in liquid nitrogen and then stored at − 80 °C until use. Tissue was homogenised in NP-
40 lysis buffer (Invitrogen, Australia), containing ß-glycerophosphate and 
pheylmethanesulfonylfluoride and protease inhibitor cocktail (Sigma). Protein concentration was 
determined by DC assay (Bio-Rad), according to the manufacturer's instructions. All animal 
experiments in this study were approved by the University of Wollongong Animal Ethics Committee 
 
(AE10/18) and complied with the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes. 
2.3. Immunoblot analyses 
Immunoblotting was performed on total homogenates as described previously (Matosin et al., 2013), 
with minor modifications optimised for the measurement of each protein of interest. Each lane was 
loaded with 5 μg (human) or 10 μg (animal) of total protein. These protein concentrations were 
determined to be in the linear range of detection (data not shown). Relative protein densities were 
determined by immunoblot analyses using polyclonal antibodies as previously reported: mGluR5 
[ABCAM ab27190; human 1:250, rat 1:500 (Matosin et al., 2013)], Norbin [ABCAM ab130507; 
human and rat 1:500], and Tamalin [ABCAM ab30576; human 1:100, rat 1:1000 (Tai et al., 2010)]. 
mGluR5 monomer was detected at 135 kDa whilst the mGluR5 dimer was detected at 270 kDa. 
Individual bands were totalled before normalisation to respective ß-actin and pooled samples to gain a 
measure of total mGluR5. Samples were visualised using an enhanced chemiluminescent detection kit 
(Bio-Rad). Band density was detected by the Gel Doc 2200 Pro (Carestream Molecular Imaging, 
USA) and quantified with Carestream MI software (v 5.0.4.44, Carestream Molecular Imaging). All 
bands were within the limits of saturation. Protein measures were subsequently normalised to their 
respective ß-actin density. Experiments and quantification were performed blind to diagnosis (human) 
or treatment group (rat). 
2.4. Statistical analyses 
Statistical analyses were performed with SPSS software (v19.0). The level of significance was set to 
p < 0.05 and data are presented as mean ± SEM. 
2.4.1. Human brain statistical analyses 
Distributions of mGluR5 total measures (but not individual monomer or dimer measures) as well as 
Norbin and Tamalin were skewed to the right (Kolmogorov–Smirnov; d = 0.152–0.246, p < 0.001). 
Normalised distribution for these proteins was therefore achieved by transforming to the natural 
logarithm of the relative protein values. Outliers were screened as mean ± 2 standard deviations and 
removed. Analyses of Variance (ANOVA) were used to detect differences in protein expression 
between diagnostic groups (schizophrenia/control) as well as gender (male/female), hemisphere 
(left/right) and antidepressant history (yes/no) for each target. Spearman's correlations were used to 
determine whether sample characteristics (Table 2) were associated with protein measures, and to 
examine if additional measures of disease characteristics were correlated specifically with the 
schizophrenia group (lifetime APD history, age of disease onset and duration of illness). Analyses of 
covariance (ANCOVA) for diagnostic effects on protein expression were subsequently performed, 
accounting for sample characteristics that were associated with protein measures. Further Spearman's 
 
correlations were performed to determine the strength of associations between mGluR5 measures and 
its trafficking molecules in schizophrenia compared to control subjects. 
2.4.2. Animal brain statistical analyses 
Values for mGluR5 (total) and Norbin were skewed to the right (Kolmogorov–Smirnov; d = 0.103–
0.169, p < 0.001), and thus were normalised by converting to the natural logarithm. Protein 
differences between treatment (haloperidol/olanzapine/vehicle) and duration (short term/medium 
term/long term) were analysed by two-way ANOVA. 
3. Results 
3.1. Protein levels of mGluR5 in schizophrenia subjects compared to controls 
We detected a robust increase in mGluR5 protein levels in the CA1 region of schizophrenia subjects 
compared to controls (total: + 42%, F1,37 = 138.579, p < 0.001;monomer: + 25%, F1,37 = 7.194, 
p = 0.011; dimer: + 52%, F1,37 = 51.705, p < 0.001;Fig. 1). Demographic and clinical measures that 
correlated significantly with mGluR5 protein levels (Table 2) were assessed for their influence on the 
data. After co-varying for freezer storage time and brain pH, which significantly correlated with 
mGluR5 (total and dimer), significant differences between schizophrenia and control were maintained 
(mGluR5 total: F1,35 = 172.974, p < 0.001; mGluR5 dimer: F1,35 = 59.433, p < 0.001). An effect of 
gender was observed, whereby mGluR5 total protein was decreased in male subjects independent of 
diagnosis (F1,37 = 5.357, p = 0.026; − 35.5%); however, there was no gender-specific difference in 
mGluR5 protein levels within the schizophrenia or control groups, and no hemispheric differences in 
mGluR5 protein expression  
3.2. Protein levels of mGluR5 trafficking molecules, Norbin and Tamalin, in schizophrenia subjects 
compared to controls 
Norbin and Tamalin proteins were identified at the expected molecular weights (79 kDa and 96 kDa 
respectively; Fig. 2). Protein levels of these mGluR5 trafficking molecules were significantly 
increased in schizophrenia (Fig. 2). Specifically, Norbin was increased by 46.7% (F1,37 = 19.600, 
p < 0.001) and Tamalin by 34.0% (F1,37 = 7.630, p = 0.009). There were no effects of gender or 
hemisphere on Norbin or Tamalin. Considering the nature of our results whereby all measured 
proteins of interest were increased, we further analysed protein levels of α-tubulin as a negative 
control to eliminate the possibility of a global protein increase within the schizophrenia samples. 
Protein levels of α-tubulin (05-829, Millipore) were not significantly different between schizophrenia 
and control subjects (F1,37 = 1.991, p = 0.167), validating our findings of increased mGluR5 and 
mGluR5 trafficking molecules. 
 
 
3.3. Effects of clinical and demographic variables, and premortem medication estimates on protein 
measures 
Spearman's correlations were performed to determine any relationships between demographic/clinical 
variables and protein levels of mGluR5 (total, monomer and dimer), Norbin and Tamalin (Table 2). 
There was a significant correlation between mGluR5 total protein and brain pH in all subjects, but this 
was not maintained in the individual diagnostic groups. There was an effect of freezer storage time on 
mGluR5 total and dimer levels. A significant negative correlation was observed between lifetime 
antipsychotic drug dose and mGluR5 monomer levels in schizophrenia subjects; this association was 
also trending for mGluR5 dimer levels. APD measures did not correlate with Norbin or Tamalin 
protein levels. Lastly, there were no effects of antidepressant medication (yes/no; F17–18 ≥ 0.015, 
p ≥ 0.189) on mGluR5, Norbin or Tamalin protein levels. 
3.4. Relationships of mGluR5 protein (total, monomer and dimer) with Norbin and Tamalin in 
schizophrenia subjects compared to controls 
Spearman's correlations were performed to determine the presence or loss of associations between 
mGluR5 and its trafficking molecules in control and schizophrenia subjects (Table 3). Although 
mGluR5 monomer and dimer levels were strongly and positively correlated in both control and 
schizophrenia subjects (r ≥ 0.790, p ≤ 0.001), there were no correlations between measures of 
mGluR5 (total, monomer or dimer) and its trafficking molecules in control or schizophrenia groups. 
3.5. Protein levels of mGluR5 and its trafficking molecules in the hippocampus of APD treated rats 
To assess the effects of current antipsychotic medications on the mGluR5 system, two-way ANOVA 
were used to compare the effects of haloperidol and olanzapine treatment (8, 16 or 36 days) on protein 
levels of mGluR5 (total, monomer or dimer), Norbin and Tamalin proteins in the hippocampus. There 
were no significant effects of olanzapine or haloperidol treatment overall or following the specific 
treatment periods (F ≥ 0.229, p ≥ 0.296). 
4. Discussion 
In the present study, we provide the first evidence that protein expression of mGluR5 is significantly 
higher (total: 42%; monomer: 25%; dimer: 52%) in the hippocampal CA1 region 
of schizophrenia subjects relative to healthy controls. Schizophrenia subjects also show a marked 
increase in Norbin, and Tamalin proteins (47% and 34% respectively), which 
are endogenous regulators of mGluR5 signalling and trafficking not before analysed in 
neuropsychiatric pathology. In addition, we found no influence of APD treatment on 
mGluR5 regulatory proteins in human subjects, however a negative association between lifetime APD 
dose and mGluR5 protein expression levels was observed in schizophrenia subjects. There were no 
alterations in mGluR5 or its trafficking molecules in the hippocampus in response to APD treatment 
in our animal model. 
 
 
mGluR5 activation in CA1 is critically involved in cognitive functions via mGluR5-mediated 
modulation of synaptic plasticity (Mukherjee and Manahan-Vaughan, 2013). mGluR5 knockout mice 
display deficits in CA1-dependent LTP, coupled with deficits in spatial learning and memory (Lu et 
al., 1997). mGluR5 PAMs, which upregulate mGluR5 activity, have been reported to enhance 
hippocampal-dependent LTP and LTD in the CA1 region, congruent with improved performance in 
the Morris water maze, a measure of hippocampal-dependent spatial learning (Ayala et al., 2009). 
mGluR5-dependent differences in spatial learning in rats correlated with measures of synaptic 
plasticity in CA1 and with mGluR5 protein levels (Manahan-Vaughan and Braunewell, 2005). As 
cognitive dysfunction is a common symptom among schizophrenia patients (Harvey, 2013), the 
observed increase in mGluR5 in the present study likely represents a compensatory upregulation for 
mGluR5 dysfunction in this region or in response to wider deficits in glutamatergic signalling. As 
recently reviewed by Hu et al. (2014), reductions in the ionotropic glutamatergic 
receptors, NMDA (Vrajová et al., 2010), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA; Eastwood et al., 1995 and Eastwood et al., 1997) and kainate (Benes et al., 2001), have been 
reported in the hippocampus. Although one study also reported no changes in these receptors (Breese 
et al., 1995), it is notable that there has been no increase detected. 
In support of a deficit in mGluR5, Timms et al. recently reported the presence of a missense 
mutation in the mGluR5 gene in a schizophrenia pedigree, transmitting to the extracellular domain of 
the mGluR5 protein and likely altering mGluR5 sensitivity to glutamate (Timms et al., 2013). 
Additionally, the authors reported a frame-shift mutation (P1148fs) that caused deletion of the 
Tamalin-binding site on the carboxyl tail of mGluR5, disrupting Tamalin/mGluR5 interactions and 
increasing mGluR5 internalisation in primary hippocampal cultures (Timms et al., 2013). We have 
also recently discovered the significant association of a single nucleotide polymorphism, located in 
the regulatory3′ untranslated region (highly involved in regulation of protein–protein interactions) 
within the GRM5 gene, and schizophrenia in a Caucasian case–control population (unpublished 
results). Considering this evidence, Tamalin (but also Norbin) proteins might be upregulated in 
schizophrenia to compensate for reduced protein–protein interactions. Whilst Norbin has been 
previously demonstrated to positively regulate mGluR5 signalling (Wang et al., 2009), both Norbin 
and Tamalin are also critical regulators of mGluR5 trafficking (Kitano et al., 2002 and Wang et al., 
2009). Therefore our finding of increased levels of these proteins further support that mGluR5 
signalling might be altered in the CA1 region of schizophrenia subjects, and these trafficking 
molecules are upregulated in an attempt to compensate for alterations to mGluR5 signalling and 
trafficking. 
 
Although it is accepted that mGluR5 is expressed on the postsynaptic neuronal membrane, increasing 
evidence supports that the majority (60–90%) of mGluR5 is distributed at intracellular locations, 
including the endoplasmic reticulum membrane and nuclear membrane (Jong et al., 2014). Depending 
on its cellular location, mGluR5 reportedly activates different signalling cascades leading to unique 
 
cellular responses (Jong et al., 2014). Accordingly, intracellular and extracellular mGluR5 
differentially mediate synaptic plasticity in the CA1: cell surface receptors contribute to both LTD 
and LTP, whereas activation of intracellular mGluR5 is involved in LTD only (Purgert et al., 2014). 
Considering our finding of alterations to proteins that regulate mGluR5 movement to/from neuronal 
membranes, using total homogenate preparations, it will be important to determine whether the 
increase in mGluR5 observed in this study represents increases in intracellular or cell-
surface distribution of mGluR5, or both. 
 
Premortem APD exposure can influence molecular measures in postmortem tissue analyses. In the 
present study, estimated lifetime APD exposure was negatively correlated with mGluR5 monomer 
levels and a correlation approaching significance was observed with mGluR5 dimers. This finding 
suggests an influence of APD on mGluR5 protein levels in the CA1 whereby APDs might act to 
reduce mGluR5 protein levels in the CA1. However considering we conversely detected increased 
mGluR5 protein levels in this region, and we found no influence of APD treatment on mGluR5 in the 
hippocampus of APD treated rats, it is unlikely that APD exposure is confounding the results of our 
study. Furthermore, we additionally report no association between Norbin, Tamalin, and APDs in our 
present human or rat studies, and we have previously reported that mGluR5 binding was not 
associated with APD exposure in the hippocampus (Matosin et al., 2013). Thus although an 
interaction is unlikely, additional studies are required to explore the mechanism underlying a potential 
association. Further investigation of the consequences of APD treatment on the mGluR5 system in 
animal models of schizophrenia would be valuable. 
 
mGluR5 is a promising therapeutic target for the treatment of cognitive deficits in schizophrenia 
(Matosin and Newell, 2013). The present study reports that mGluR5 and mGluR5 trafficking 
molecules are altered in the CA1 region in subjects with schizophrenia, suggesting that mGluR5 
signalling and trafficking is altered. It will be important for future studies to elucidate the exact 
mechanisms underlying these alterations and their implications for novel mGluR5-targeting 
therapeutics, to determine how to best target mGluR5 (if at all) in a manner that will be therapeutic in 
the context of pathological alterations. For example, altered cell surface expression might limit 
available targets for drugs aimed at mGluR5 and the use of pharmacological chaperones to attenuate 
mGluR5 trafficking deficits may be beneficial (Ulloa-Aguirre and Conn, 2011), whilst insensitivity to 
glutamate (as proposed by Timms et al., 2013) may positively or negatively affect PAMs that rely on 
simultaneous glutamate activation. 
 
We conclude that hippocampal CA1 protein levels of mGluR5 and mGluR5 trafficking molecules are 
increased in the pathology of schizophrenia. We hypothesise that this may be related to a functional 
deficit within mGluR5, whereby glutamate sensitivity, protein–protein interactions or mGluR5 
localisation are affected. Due to the prominent role of hippocampal mGluR5 in the emergence of 
learning and memory deficits, we further suggest that alterations to mGluR5 in CA1 may be 
 
associated with an imbalance of LTD:LTP, thus contributing to cognitive dysfunctions that are 
observed in schizophrenia patients. However, future studies investigating the correlation between 
hippocampal mGluR5 expression and cognition in humans are required to confirm this hypothesis. 
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Figures and Tables 
 
 
Figure 1. Protein levels of mGluR5 in the CA1 region of subjects with schizophrenia and 
matched controls. (a) Representative immunoblots, and normalised levels of mGluR5 (b) total, (c) 
monomer, and (d) dimer protein measures, in schizophrenia subjects compared to controls. 
Abbreviations: Ct: control; kDa: kilodaltons; Ln: natural logarithm; mGluR5: metabotropic 
glutamate receptor 5; Sz: schizophrenia. *P<0.05, **P<0.01, ***P<0.001. 
  
 
 
 
Figure 2. mGluR5 trafficking molecules Norbin and Tamalin in the CA1 region of subjects with 
schizophrenia. (a) Representative immunoblots, and normalised protein levels of mGluR5 trafficking 
molecules (b) Norbin and (c) Tamalin in the CA1 region of subjects with schizophrenia compared to 
matched controls. Abbreviations: Ct: control; kDa: kilodaltons; Ln: natural logarithm; Sz: 
schizophrenia. *P<0.05, **P<0.01, ***P<0.001. 
 
  
 
 
 
Table 1. Demographic and clinical characteristics of the postmortem cohort. 
  
CA1 (n=20/group) 
Control Schizophrenia 
Brain pH 6.6 ± 0.03 6.6 ± 0.3 
Postmortem interval (hours) 26.1 ± 12.8 28.8 ± 14.1 
RNA integrity number 7.2 ± 0.7 7.2 ± 0.5 
Age at Death (years) 58.2 ± 12.6  55.5 ± 13.5 
Gender 2 F, 18 M 9 F, 11 M 
Hemisphere 13 R, 7L 10R, 10L 
Age of disease onset (years) - 23.5 ± 6.8 
Duration of illness (years) - 32.05 ± 13.7 
Lifetime antipsychotic drug medication*  - 668 ± 421 
Antidepressant history (yes/no) - 12 
*Standardised chlorpromazine equivalent, mg.  
Abbreviations: DLPFC: dorsolateral prefrontal cortex; F: female; L: left; M: 
male; R: right. Data are expressed as mean ± standard deviation 
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Table 2. Spearman's Correlations for continuous clinical and demographic variables and 
protein levels of mGluR5 total, monomer and dimer, and mGluR5 trafficking molecules 
Norbin and Tamalin, in the hippocampal CA1 region. Significant values (p<0.05) are 
highlighted in bold. 
Variable  
All subjects Controls Schizophrenia 
mGlu
R5 
(total) 
mGlu
R5 
(mono
mer) 
mGlu
R5 
(dimer
) 
Norbi
n 
Tama
lin 
mGlu
R5 
(total)
mGlu
R5 
(mono
mer) 
mGlu
R5 
(dimer
) 
Norbi
n 
Tam
alin 
mGlu
R5 
(total)
mGlu
R5 
(mono
mer) 
mGlu
R5 
(dimer
) 
Norbi
n 
Tama
lin 
Brain pH  
r = -
0.355 
r = -
0.001 
r =-
0.088 
r = 
0.015 
r = 
0.026
r = -
0.304
r = -
0.040 
r = -
0.134 
r = 
0.142 
r = 
0.127
r = -
0.448 
r = -
0.084 
r =-
0.116 
r = -
0.170 
r = -
0.147
   
p = 
0.026 
p = 
0.993 
p 
=0.593 
p = 
0.929 
p = 
0.874
p = 
0.192
p = 
0.867 
p = 
0.573 
p = 
0.551 
p = 
0.593
p = 
0.055 
p = 
0.732 
p = 
0.497 
p = 
0.486 
p = 
0.549
Age at Death  
r = -
0.028 
r = -
0.154 
r =-
0.164 
r = -
0.096 
r = -
0.096
r = -
0.188
r = -
0.087 
r = 
0.136 
r = -
0.068 
r = -
0.061
r = 
0.287 
r = -
0.184 
r = -
0.211 
r = -
0.199 
r = -
0.187
   
p = 
0.868 
p = 
0.349 
p = 
0.320 
p = 
0.561 
p = 
0.560
p = 
0.427
p = 
0.716 
p = 
0.569 
p = 
0.777 
p = 
0.798
p = 
0.233 
p 
=0.452 
p = 
0.386 
p = 
0.414 
p = 
0.444
Postmortem 
interval  
r = -
0.167 
r = 
0.100 
r = 
0.170 
r = -
0.051 
r = -
0.085
r = -
0.199
r = -
0.199 
r = -
0.118 
r = 
0.113 
r = 
0.049
r = -
0.328 
r = 
0.250 
r = 
0.359 
r = -
0.158 
r = -
0.170
   
p = 
0.309 
p = 
0.546 
p = 
0.302 
p = 
0.758 
p = 
0.606
p = 
0.400
p = 
0.401 
p = 
0.620 
p = 
0.635 
p = 
0.838
p = 
0.170 
p = 
0.302 
p = 
0.131 
p = 
0.517 
p = 
0.487
Freezer 
storage time  
r = 
0.356 
r 
=0.243
r = 
0.347 
r = 
0.173 
r = 
0.159
r = 
0.274
r = 
0.335 
r = 
0.332 
r = 
0.219 
r = 
0.162
r = 
0.531
r = 
0.207 
r = 
0.354 
r = 
0.220 
r = 
0.210
   
p = 
0.026 
p 
=0.136
p 
=0.030 
p = 
0.292 
p = 
0.334
p = 
0.243
p = 
0.149 
p = 
0.152 
p = 
0.354 
p = 
0.496
p = 
0.019
p 
=0.395 
p = 
0.137 
p = 
0.365 
p = 
0.389
Brain weight  
r = -
0.144 
r = -
0.039 
r = -
0.232 
r = -
0.258 
r = -
0.176
r = -
0.267
r = -
0.083 
r = -
0.170 
r = -
0.123 
r = -
0.042
r = 
0.030 
r = -
0.069 
r = -
0.194 
r = -
0.145 
r = -
0.142
   
p = 
0.383 
p = 
0.815 
p = 
0.156 
p = 
0.113 
p = 
0.283
p = 
0.255
p = 
0.729 
p 
=0.473
p = 
0.606 
p = 
0.860
p = 
0.903 
p = 
0.780 
p = 
0.425 
p = 
0.553 
p = 
0.563
Age of 
disease onset  - - - - - - - - - - 
r = 
0.259 
r = 
0.241 
r = 
0.156 
r = 
0.051 
r = 
0.078
   - - - - - - - - - - 
p = 
0.285 
p = 
0.321 
p = 
0.523 
p = 
0.837 
p = 
0.750
Duration of 
illness  - - - - - - - - - - 
r = 
0.199 
r = -
0.234 
r = -
0.232 
r = -
0.231 
r = -
0.224
   - - - - - - - - - - 
p = 
0.415 
p = 
0.336 
p = 
0.339 
p = 
0.341 
p = 
0.357
Lifetime 
antipsychotic 
drug intake*  
- - - - - - - - - - 
r = -
0.160 
r = -
0.502 
r = -
0.426 
r = -
0.251 
r = -
0.256
- - - - - - - - - - 
p = 
0.514 
p = 
0.029 
p = 
0.069 
p = 
0.300 
p = 
0.290
* Standardised chlorpromazine equivalent (mg) 
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Table 3. Spearman’s correlations for associations between protein levels of mGluR5 (total, 
monomer and dimer) and novel mGluR5 signalling partners Norbin and Tamalin, within (A) 
control and (B) schizophrenia subjects. Significant values (p<0.05) are highlighted in bold. 
A. Control mGluR5 total mGluR5 monomer mGluR5 dimer 
mGluR5 (total)  -  r = 0.066 r = 0.102 
 -  p = 0.782 p = 0.668 
mGluR5 (monomer) r = 0.066  -  r = 0.853 
p = 0.782  -  p < 0.001 
mGluR5  (dimer) r = 0.102 r = 0.853  -  
p = 0.668 p < 0.001  -  
Norbin r = -0.036 r = 0.274 r = 0.266 
p = 0.980 p = 0.243 p = 0.257 
Tamalin r = 0.017 r = 0.334 r = 0.292 
p = 0.945 p = 0.150 p = 0.212 
    
B. Schizophrenia mGluR5 total mGluR5 monomer mGluR5 dimer 
mGluR5(total)  -  r = 0.140 r = 0.137 
 -  p = 0.557 p = 0.566 
mGluR5(monomer) r = 0.140  -  r = 0.790
p = 0.557  -  p < 0.001 
mGluR5 (dimer) r = 0.137 r = 0.790  -  
p = 0.566 p < 0.001  -  
Norbin r = 0.037 r = 0.001 r = 0.064 
p = 0.876 p = 0.996 p = 0.788 
Tamalin r = 0.027 r = 0.038 r = 0.029 
p = 0.910 p = 0.875 p = 0.902 
 
	
